Comparison between 5-aminolevulinic acid photodynamic diagnosis and narrow-band imaging for bladder cancer detection.
Aged
Aged, 80 and over
Cystoscopy
/ methods
Female
Humans
Levulinic Acids
/ administration & dosage
Male
Middle Aged
Narrow Band Imaging
Photosensitizing Agents
/ administration & dosage
Retrospective Studies
Sensitivity and Specificity
Urinary Bladder Neoplasms
/ diagnostic imaging
Aminolevulinic Acid
5-aminolevulinic acid
Bladder cancer
Narrow-band imaging
Photodynamic diagnosis
Transurethral resection of bladder tumour
Journal
BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571
Informations de publication
Date de publication:
22 Dec 2021
22 Dec 2021
Historique:
received:
31
07
2021
accepted:
14
12
2021
entrez:
23
12
2021
pubmed:
24
12
2021
medline:
23
2
2022
Statut:
epublish
Résumé
To compare 5-aminolevulinic acid (5-ALA)-mediated photodynamic diagnosis (PDD) with narrow-band imaging (NBI) for cancer detection during transurethral resection of bladder tumour (TURBT). Between June 2018 and October 2020, 114 patients and 282 lesions were included in the analysis. Patients were orally administered 5-ALA (20 mg/kg) 2 h before TURBT. The bladder was inspected with white light (WL), PDD, and NBI for each patient, and all areas positive by at least one method were resected or biopsied. The imaging data were then compared to the pathology results. The sensitivities of WL, PDD, and NBI for detecting urothelial carcinoma were 88.1%, 89.6%, and 76.2%, respectively. The specificity, positive predictive value, and negative predictive value for detecting urothelial carcinoma were 47.5%, 80.9%, and 61.3%, respectively, for WL; 22.5%, 74.5%, and 46.2%, respectively, for PDD; and 46.3%, 78.2%, and 43.5%, respectively, for NBI. PDD was significantly more sensitive than NBI for all lesions (p < 0.001) and carcinoma in situ (CIS) lesions (94.6% vs. 54.1%, p < 0.001). PDD can increase the detection rate of bladder cancer, compared to NBI, by greater than 10%. Therefore, 100% of CIS lesions can be detected by adding PDD to WL.
Sections du résumé
BACKGROUND
BACKGROUND
To compare 5-aminolevulinic acid (5-ALA)-mediated photodynamic diagnosis (PDD) with narrow-band imaging (NBI) for cancer detection during transurethral resection of bladder tumour (TURBT).
METHODS
METHODS
Between June 2018 and October 2020, 114 patients and 282 lesions were included in the analysis. Patients were orally administered 5-ALA (20 mg/kg) 2 h before TURBT. The bladder was inspected with white light (WL), PDD, and NBI for each patient, and all areas positive by at least one method were resected or biopsied. The imaging data were then compared to the pathology results.
RESULTS
RESULTS
The sensitivities of WL, PDD, and NBI for detecting urothelial carcinoma were 88.1%, 89.6%, and 76.2%, respectively. The specificity, positive predictive value, and negative predictive value for detecting urothelial carcinoma were 47.5%, 80.9%, and 61.3%, respectively, for WL; 22.5%, 74.5%, and 46.2%, respectively, for PDD; and 46.3%, 78.2%, and 43.5%, respectively, for NBI. PDD was significantly more sensitive than NBI for all lesions (p < 0.001) and carcinoma in situ (CIS) lesions (94.6% vs. 54.1%, p < 0.001).
CONCLUSIONS
CONCLUSIONS
PDD can increase the detection rate of bladder cancer, compared to NBI, by greater than 10%. Therefore, 100% of CIS lesions can be detected by adding PDD to WL.
Identifiants
pubmed: 34937543
doi: 10.1186/s12894-021-00946-w
pii: 10.1186/s12894-021-00946-w
pmc: PMC8693495
doi:
Substances chimiques
Levulinic Acids
0
Photosensitizing Agents
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
180Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71:96–108. https://doi.org/10.1016/j.eururo.2016.06.010 .
doi: 10.1016/j.eururo.2016.06.010
Lenis AT, Lec PM, Chamie K. Bladder cancer: a review. JAMA. 2020;324:1980–91. https://doi.org/10.1001/jama.2020.17598 .
doi: 10.1001/jama.2020.17598
pubmed: 33201207
pmcid: 33201207
Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström P, Choi W, et al. Bladder cancer. Lancet. 2016;388:2796–810. https://doi.org/10.1016/S0140-6736(16)30512-8 .
doi: 10.1016/S0140-6736(16)30512-8
pubmed: 27345655
pmcid: 27345655
Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71:447–61. https://doi.org/10.1016/j.eururo.2016.05.041 .
doi: 10.1016/j.eururo.2016.05.041
pubmed: 27324428
pmcid: 27324428
Kriegmair M, Baumgartner R, Knüchel R, Stepp H, Hofstädter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol. 1996;155:105–9 (discussion 9–10).
doi: 10.1016/S0022-5347(01)66559-5
Filbeck T, Roessler W, Knuechel R, Straub M, Kiel HJ, Wieland WF. Clinical results of the transurethreal resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid. J Endourol. 1999;13:117–21. https://doi.org/10.1089/end.1999.13.117 .
doi: 10.1089/end.1999.13.117
pubmed: 10213106
pmcid: 10213106
De Dominicis C, Liberti M, Perugia G, De Nunzio C, Sciobica F, Zuccalà A, et al. Role of 5-aminolevulinic acid in the diagnosis and treatment of superficial bladder cancer: improvement in diagnostic sensitivity. Urology. 2001;57:1059–62. https://doi.org/10.1016/s0090-4295(01)00948-7 .
doi: 10.1016/s0090-4295(01)00948-7
pubmed: 11377304
pmcid: 11377304
Zaak D, Kriegmair M, Stepp H, Stepp H, Baumgartner R, Oberneder R, et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology. 2001;57:690–4. https://doi.org/10.1016/s0090-4295(00)01053-0 .
doi: 10.1016/s0090-4295(00)01053-0
pubmed: 11306382
pmcid: 11306382
Naselli A, Introini C, Timossi L, Spina B, Fontana V, Pezzi R, et al. A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. Eur Urol. 2012;61:908–13. https://doi.org/10.1016/j.eururo.2012.01.018 .
doi: 10.1016/j.eururo.2012.01.018
pubmed: 22280855
pmcid: 22280855
Kutwin P, Konecki T, Cichocki M, Falkowski P, Jabłonowski Z. Photodynamic diagnosis and narrow-band imaging in the management of bladder cancer: a review. Photomed Laser Surg. 2017;35:459–64. https://doi.org/10.1089/pho.2016.4217 .
doi: 10.1089/pho.2016.4217
pubmed: 28537820
pmcid: 28537820
Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA, et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol. 2012;188:58–62. https://doi.org/10.1016/j.juro.2012.03.007 .
doi: 10.1016/j.juro.2012.03.007
pubmed: 22583635
pmcid: 22583635
Nakai Y, Inoue K, Tsuzuki T, Shimamoto T, Shuin T, Nagao K, et al. Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: a multicenter phase III study. Int J Urol. 2018;25:723–9. https://doi.org/10.1111/iju.13718 .
doi: 10.1111/iju.13718
pubmed: 29999205
pmcid: 29999205
Yamamoto S, Fukuhara H, Karashima T, Inoue K. Real-world experience with 5-aminolevulinic acid for the photodynamic diagnosis of bladder cancer: diagnostic accuracy and safety. Photodiagn Photodyn Ther. 2020;32: 101999. https://doi.org/10.1016/j.pdpdt.2020.101999 .
doi: 10.1016/j.pdpdt.2020.101999
Xiong Y, Li J, Ma S, Ge J, Zhou L, Li D, et al. A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer. PLoS ONE. 2017;12: e0170819. https://doi.org/10.1371/journal.pone.0170819 .
doi: 10.1371/journal.pone.0170819
pubmed: 28192481
pmcid: 28192481
Babjuk M, Burger M, Capoun O, Cohen D, Comperat EM, Dominguez Escrig JL, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81:75–94. https://doi.org/10.1016/j.eururo.2021.08.010 .
doi: 10.1016/j.eururo.2021.08.010
pubmed: 34511303
pmcid: 34511303
Naya Y, Oishi M, Yamada Y, Ueda T, Fujihara A, Nakanishi H, et al. Initial experience of combined use of photodynamic diagnosis and narrow band imaging for detection of flat urothelial lesion. Int J Clin Oncol. 2015;20:593–7. https://doi.org/10.1007/s10147-014-0748-5 .
doi: 10.1007/s10147-014-0748-5
pubmed: 25228479
pmcid: 25228479
Drejer D, Béji S, Oezeke R, Nielsen AM, Høyer S, Bjerklund Johansen TE, et al. Comparison of white light, photodynamic diagnosis, and narrow-band imaging in detection of carcinoma in situ or flat dysplasia at transurethral resection of the bladder: the DaBlaCa-8 study. Urology. 2017;102:138–42. https://doi.org/10.1016/j.urology.2016.11.032 .
doi: 10.1016/j.urology.2016.11.032
pubmed: 27894979
pmcid: 27894979
Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien–Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–96. https://doi.org/10.1097/SLA.0b013e3181b13ca2 .
doi: 10.1097/SLA.0b013e3181b13ca2
pubmed: 19638912
pmcid: 19638912
Yatabe T, Marie SL, Fukuhara H, Karashima T, Inoue K, Yokoyama M. 5-aminolevulinic acid-induced severe hypotension during transurethral resection of a bladder tumor: a case report. JA Clin Rep. 2019;5:58. https://doi.org/10.1186/s40981-019-0279-1 .
doi: 10.1186/s40981-019-0279-1
pubmed: 32025993
pmcid: 32025993
Nohara T, Kato Y, Nakano T, Nakagawa T, Iwamoto H, Yaegashi H, et al. Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer. Int J Urol. 2019;26:1064–8. https://doi.org/10.1111/iju.14099 .
doi: 10.1111/iju.14099
pubmed: 31512303
pmcid: 31512303
Kanehira K, Yano Y, Hasumi H, Fukuhara H, Inoue K, Hanazaki K, et al. Fluorescence enhancement effect of TiO
doi: 10.3390/ijms20153698